Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.
dc.contributor.author | Yalcin, Suayib | |
dc.contributor.author | Dane, Faysal | |
dc.contributor.author | Oksuzoglu, Berna | |
dc.contributor.author | Yildirim, Nuriye | |
dc.contributor.author | Isikdogan, Abdurrahman | |
dc.contributor.author | Ozkan, Metin | |
dc.contributor.author | Demirag, Guzin | |
dc.date.accessioned | 2024-04-24T17:15:01Z | |
dc.date.available | 2024-04-24T17:15:01Z | |
dc.date.issued | 2018 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description | Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) -- JAN 18-20, 2018 -- San Francisco, CA | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
dc.identifier.doi | 10.1200/JCO.2018.36.4_suppl.346 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.uri | https://doi.org/10.1200/JCO.2018.36.4_suppl.346 | |
dc.identifier.uri | https://hdl.handle.net/11468/18302 | |
dc.identifier.volume | 36 | en_US |
dc.identifier.wos | WOS:000436174100331 | |
dc.identifier.wosquality | Q1 | |
dc.indekslendigikaynak | Web of Science | |
dc.language.iso | en | en_US |
dc.publisher | Lippincott Williams & Wilkins | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keyword] | en_US |
dc.title | Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study. | en_US |
dc.title | Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study. | |
dc.type | Conference Object | en_US |